Literature DB >> 22727901

The role of clinical versus histopathological staging in patients with advanced oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy followed by radical surgery.

Matthias Kreppel1, Timo Dreiseidler, Daniel Rothamel, Hans-Theodor Eich, Uta Drebber, Joachim E Zöller, Martin Scheer.   

Abstract

INTRODUCTION: Several studies have questioned the prognostic accuracy of the TNM system for oral cancer since neither patient's comorbidity, specific tumor related factors nor multimodal treatment regimens such as preoperative radiochemotherapy (RCT) are incorporated. The present study was performed in order to evaluate the prognostic impact of cTNM and ypTNM in oral cancer patients treated with preoperative RCT and resection.
METHODS: In this retrospective analysis a total of 139 patients (103 male, 36 female, average age 56.8 years) with oral squamous cell carcinoma (UICC II-IVb) were included. Treatment consisted of concomitant RCT with 39.6 Gy radiations and Carboplatin (cumulative dose 300 mg/m(2)) during the first week of radiation, as well as surgical tumor resection and neck dissection.
RESULTS: During the mean follow up of 88.9 months 86 patients (61.9%) died. Locoregional recurrences occurred in 41 patients (29.5%). The 5 years overall survival rate was 45.5%. In univariate analysis margin status, ypT, ypN and ypUICC as well as complete pathological response revealed statistical significance on overall survival. In multivariate analysis ypT, ypN and margin status showed independent prognostic impact in our cohort. Neither cT nor cN provided statistical association with overall survival.
CONCLUSION: Results indicate that the clinical staging status of advanced oral cancer prior to preoperative RCT and resection should be interpreted with caution in terms of prognosis.
Copyright © 2012 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727901     DOI: 10.1016/j.jcms.2012.05.005

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  6 in total

1.  A novel histopathological scoring system for patients with oral squamous cell carcinoma.

Authors:  Ali-Farid Safi; Kathrin Grochau; Uta Drebber; Volker Schick; Oliver Thiele; Tim Backhaus; Hans-Joachim Nickenig; Joachim E Zöller; Matthias Kreppel
Journal:  Clin Oral Investig       Date:  2019-01-23       Impact factor: 3.573

2.  [Renaissance of pedicled flaps in oral and maxillofacial surgery].

Authors:  M Twieg; W Reich; R Dempf; A W Eckert
Journal:  Chirurg       Date:  2014-06       Impact factor: 0.955

3.  Influence of tumor volume on survival in patients with oral squamous cell carcinoma.

Authors:  Thomas Mücke; David A Mitchell; Lucas M Ritschl; Andrea Tannapfel; Klaus-Dietrich Wolff; Marco R Kesting; Denys J Loeffelbein; Anastasios Kanatas
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-26       Impact factor: 4.553

Review 4.  Will the mininvasive approach challenge the old paradigms in oral cancer surgery?

Authors:  G Tirelli; S Zacchigna; F Boscolo Nata; E Quatela; R Di Lenarda; M Piovesana
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-04       Impact factor: 2.503

5.  Analysis of clinicopathological characteristics associated with the outcome of oral squamous cell carcinoma and the establishment of tissue microarrays.

Authors:  Xin Jin; Dongjuan Liu; Xin Zhao; Yu Zhou; Lu Jiang; Jing Li; Xin Zeng; Qianming Chen
Journal:  Oncol Lett       Date:  2016-09-12       Impact factor: 2.967

6.  Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial.

Authors:  Jens von der Grün; Ria Winkelmann; Iris Burck; Daniel Martin; Franz Rödel; Peter Johannes Wild; Katrin Bankov; Andreas Weigert; Ivan-Maximiliano Kur; Christian Brandts; Natalie Filmann; Christian Issing; Philipp Thönissen; Anna Maria Tanneberger; Claus Rödel; Shahram Ghanaati; Panagiotis Balermpas
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.